Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
t(11;14)(q13;q32) in multiple myeloma Atlas of Genetics and Cytogenetics in Oncology and Haematology Huret JL, Laï JL OPEN ACCESS JOURNAL AT INIST-CNRS Gene Section Review HLA-G (major histocompatibility complex, class I, G) Shang-Mian Yie The Second Medical College/Teaching Hospital, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, PR China (SMY) Published in Atlas Database: January 2012 Online updated version : http://AtlasGeneticsOncology.org/Genes/HLAGID43744ch6p22.html DOI: 10.4267/2042/47338 This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. © 2012 Atlas of Genetics and Cytogenetics in Oncology and Haematology located approximately 1,2 kb from the ATG initiation codon of the HLA-G gene. The CREB1 factor binds to this region (-1380/-1370), as well as to two additional cAMP response elements (CRE) dispersed through the promoter region at positions -934 and -770 from the ATG. An interferon-sensitive response element (ISRE) is located at position -744 from the ATG (Lefebvre et al., 2001). A heat shock element (HSE) is located within the HLA-G promoter at position -459/-454 that binds heat shock factor 1 (HSF-1) (Ibrahim et al., 2000). A progesterone receptor response element (PRE) is located at position -37 from the ATG (Yie et al., 2006), and three ras response elements (RRES) are situated along the HLA-G gene promoter (-1356, -142, -53) (Flajollet et al., 2009). The 3'-UTR of the HLA-G gene also exhibits several regulatory elements including AU-rich motifs and a poly-A signal to influence mRNA stability, turnover, mobility and splicing pattern (Donadi et al., 2011). The primary transcript of HLA-G can be spliced into 7 alternative mRNAs (figure 1D) that encode membranebound (HLA-G1, -G2, -G3, -G4) and soluble (HLAG5, -G6, -G7) protein isoforms (Carosella et al., 2003). HLA-G1 is the full-length HLA-G molecule, HLA-G2 lacks exon 3, HLA-G3 lacks exons 3 and 4, and HLAG4 lacks exon 4. HLA-G1 to -G4 are membrane-bound molecules due to the presence of the transmembrane and cytoplasmic tail encoded by exons 5 and 6. HLAG5 is similar to HLA-G1 but retains intron 4, HLAG6 lacks exon 3 but retains intron 4, and HLA-G7 lacks exon 3 but retains intron 2. HLA-G5 and -G6 are soluble forms due to the presence of intron 4, which contains a premature stop codon to prevent the translation of the transmembrane and cytoplasmic tail. HLA-G7 is soluble due to the presence of intron 2, which contains a premature stop codon. Identity Other names: MHC-G HGNC (Hugo): HLA-G Location: 6p22.1 DNA/RNA Description HLA-G is one of the non-classical class I (Ib) HLA molecules. The HLA-G gene is located at the short arm of chromosome 6 in the HLA region (6p21.2-21.3) between HLA-A and HLA-F genes (figure 1A). The gene structure of HLA-G is homologous to other HLA class I (Ia) genes consisting of 7 introns and 8 exons coding the heavy chain of the molecule. Exon 1 encodes the peptide signal, while exons 2, 3 and 4 encode the extracellular α1, α2 and α3 domains, respectively. Exons 5 and 6 encode the transmembrane and cytoplasmic domains of the heavy chain. Exon 7 is always absent from mature mRNA and due to the stop codon in exon 6; exon 8 is not translated (figure 1B). Transcription The functional mRNA level of a particular gene is regulated by the rate of synthesis, mainly driven by the promoter region (5'-UTR) of the given gene, as well as by the rate of degradation, stability, localization and translatability of the specific mRNA (Kuersten and Goodwin, 2003). The HLA-G gene promoter has a modified enhancer A (enhA), S and X1 sequence, and a few alternative regulatory elements to regulate HLA-G gene transcription (figure 1C). So far, these regulatory elements include the locus control region (LCR) (Schmidt et al., 1993; Yelavarthi et al., 1993), which is Atlas Genet Cytogenet Oncol Haematol. 2012; 16(6) 403 HLA-G (major histocompatibility complex, class I, G) Yie SM Figure 1. The human leukocyte antigen-G (HLA-G) gene and transcription. A. HLA-G gene location. B. HLA-G gene structure consisting of 7 introns (white color) and 8 exons (green color). C. HLA-G gene promoter exhibiting regulatory elements to regulate HLA-G gene transcription and 3'-UTR of the HLA-G gene exhibiting several regulatory elements including AU-rich motifs and a Poly-A signal to influence mRNA stability, turnover, mobility and splicing pattern. CRE stands for cAMP responsive element, RRES for ras response elements, ISRE for interferon-sensitive response element, HSE for heat shock response element, PRE for progesterone response element, and X1 for X1 box. D. HLA-G primary transcript can be spliced into 7 alternative mRNAs ranging from HLA-G1 to -G7. Atlas Genet Cytogenet Oncol Haematol. 2012; 16(6) 404 HLA-G (major histocompatibility complex, class I, G) Yie SM Figure 2. HLA-G protein and its function. A. HLA-G protein exhibits a heterodimer consisting of globular domains (α1, α2 and α3 domains, transmembrane and cytoplasmic domains) and a light chain (β2-microglobulin). B. Alternative splicing of the primary transcript yields 7 protein isoforms: truncated isoforms are generated by excision of one or two exons encoding the globular domains, whereas translation of intron 4 or intron 2 yields soluble isoforms that lack the transmembrane domain. HLA-G molecules can form homomultimers through the generation of Cys42-Cys42 or Cys42-Cys147 disulphide bonds. C. Immunoregulatory activities mediated by HLA-G, where the involved target cells and receptors are indicated. The HLA-G7 isoform has only the α1 domain linked to two amino acids encoded by intron 2, which is retained in the corresponding transcript (Fujii et al., 1994; Ishitani and Geraghty, 1992; Paul et al., 2000). In addtion, HLA-G molecules can form dimers through the creation of disulphide bonds between two unique cysteine residues at positions 42 (Cys42-Cys42 bonds) and 147 (Cys42-Cys147 bonds) of the HLA-G heavy chain (figure 2B) (Boyson et al., 2002; Gonen-Gross et al., 2003). The dimerization has an oblique orientation that exposes the HLA-G receptor binding sites of the α3 domain upwards, making them more accessible to the receptors. Consequently, HLA-G dimers bind receptors with higher affinity and slower dissociation rates than monomers, and signal more efficiently than monomers as well (Shiroishi et al., 2006). Protein Description The HLA-G protein exhibits a heterodimer consisting of globular domains (α1, α2 and α3 domains, transmembrane and cytoplasmic domains) and a light chain (β2-microglobulin) called monomer (figure 2A). However, there may be 7 protein isoforms, generated by alternative splicing of the primary transcript: four of them being membrane-bound (HLA-G1, -G2, -G3 and G4) and three soluble (HLA-G5, -G6 and -G7) (figure 2B). HLA-G1 is the complete isoform associated with β2-microglobulin. The HLA-G2 isoform has no α2 domain, while HLA-G3 has no α2 and α3 domains, and HLA-G4 has no α3 domain. The soluble HLA-G5 and G6 isoforms contain the same extra globular domains as HLA-G1 and -G2, respectively, generated by transcripts conserving intron 4, which blocks the translation of the transmembrane domain. The 5'-region of intron 4 is translated until the generation of a stop codon, which gives the HLA-G5 and -G6 isoforms a tail of 21 amino acids responsible for their solubility. Atlas Genet Cytogenet Oncol Haematol. 2012; 16(6) Expression Classical class Ia antigens are ubiquitously expressed, whereas the expression of HLA-G is restrictive. HLAG protein expression is only found in trophoblast cells in the placenta, certain immune cells (in most cases monocytes), thymus, cornea, proximal nail matrix, 405 HLA-G (major histocompatibility complex, class I, G) Yie SM KIRs are transmembrane glycoproteins expressed by natural killer cells and subsets of T cells, exhibiting two (KIR2D) or three (KIR3D) extracellular immunoglobulin-like domains, which also contain ITIMs. The KIR2DL4 binds to the α1 domain of the HLA-G molecule (Yan and Fan, 2005). However, the binding site of KIR2DL4 to HLA-G remains unknown (Donadi et al., 2011). Moreover, since an array of activator and inhibitor receptors is expressed on the surface of most NK cells and macrophages, and the final effector function is dependent on the balance between activator and inhibitor receptors (Hsu et al., 2002), the role of the interaction between KIR2DL4 and HLA-G in the modulation of the immune response has been a matter of much debate (LeMaoult et al., 2003; Apps et al., 2008). HLA-G has an inhibitory effect on cytotoxic cells exhibiting CD8 on their surface through the interaction of the α3 domain of HLA-G with the CD8 α/α molecule. The α3 domain of HLA-G is the same site of interaction with CD8 α/α and LILRBs. Even though the CD8 α/α and LILIRBs binding sites overlap, LILIRBs inhibit the binding of CD8 α/α to HLA molecules by displacing CD8 α/α and activating ITIMs (Shiroishi et al., 2003). Beside the extracellular domains of HLA-G, all segments of the molecule may contribute to its function. The short cytoplasmic tail retains HLA-G longer in the endoplasmic reticulum and prolongs the half-life of the molecule on the cell surface because of the lack of an endocytosis motif (Park et al., 2001; Park and Ahn, 2003). This permits multiple interactions with cells of the immune system. Soluble HLA-G molecule can induce apoptosis in CD8+ activated T lymphocytes as well as in CD8+ NK cells (lacking the T cell receptor) at similar rates. The binding of soluble HLA molecules to CD8 leads to apoptosis upregulating Fas production and Fas/FasL interaction (Puppo et al., 2002; Contini et al., 2003). This mechanism represents an additional immunomodulatory effect of HLA-G. erythroblasts and mesenchymal stem cells (Kovats et al., 1990; Crisa et al., 1997; Lila et al., 2001; Ishitani et al., 2003; Rebmann et al., 2003; Morandi et al., 2008). The reasons for HLA-G expression in some but not other tissues have not been fully elucidated. However, soluble HLA-G (sHLA-G) can be detected in the serum/plasma of both men and women. The main source of sHLA-G in the blood of men and nonpregnant women is most likely monocytes. Both CD4+ and CD8+ T cells and B cells also seem to be able to secrete HLA-G5 although to a lesser extent (Rebmann et al., 2003). The presence or level of sHLA-G in serum/plasma samples is associated with HLA-G polymorphism (Rebmann et al., 2001; Hviid et al., 2004a; Hviid et al., 2004b; Rizzo et al., 2005). As mentioned earlier, HLA-G expression is mainly controlled at the transcriptional level by a unique gene promoter and at the post-transcriptional level by alternative splicing, mRNA stability, translation and protein transport to the cell surface. Many factors have been described that can potentially affect transcriptional and post-transcriptional mechanisms responsible for HLA-G regulation (Moreau et al., 2009). Function It has been demonstrated that HLA-G is an immune tolerogenic molecule, which plays an important role in the suppression of the immune responses (Carosella et al., 2008) (figure 2C). The immune-inhibitory function of HLA-G is realized by interacting with leukocyte receptors including leukocyte immunoglobulin-like receptor subfamily B member 1 (LILRB1) and member 2 (LILRB2), and killer cell immunoglobulin-like receptor 2DL4 (KIR2DL4) (Shiroishi et al., 2006; Gao et al., 2000). LILRB1s are expressed on the surface of several leukocytes, such as NK and lymphomononuclear cells, while LILRB2s are primarily expressed on the surface of a restricted set of cells, including monocytes and dendritic cells (Brown et al., 2004). Both LILRB1 and LILRB2 have several inhibitory motifs (ITIM) receptors based on the immunoreceptor tyrosine in their cytoplasmic tail, which inhibits signaling events triggered by stimulatory receptors (Dietrich et al., 2001). LILRB1 and LILRB2 both interact with classical HLA class I molecules. However, their binding with HLA-G presents three- to four-fold higher affinity when compared to classical molecules (Shiroishi et al., 2003). LILRB1 and LILRB2 also bind to the α3 domain and β2-microglobulin of the HLA-G molecule, although LILRB2 binds with higher affinity than LILRB1. LILRB2 binds more to the α3 domain than to the β2-microglobulin domain. The binding sites of LILRB1 and LILRB2 are distinct. The Tyr36 and Arg38 residues of LILRB2 bind to the 195-197 loop of the α3 domain of HLA-G, whereas the Tyr38 and Tyr76 residues of LILRB1 bind to the Phe195 of HLAG (Shiroishi et al., 2006). Atlas Genet Cytogenet Oncol Haematol. 2012; 16(6) Mutations Somatic 44 HLA-G coding alleles have been defined based upon 72 single nucleotide polymorphisms (SNP) observed between exon 1 and intron 6. Nucleotide variability in the coding region of the HLA-G gene is evenly distributed throughout exons 2, 3 and 4, as well as in introns (Donadi et al., 2011). The heavy chain encoding region exhibits 33 SNPs but only 13 amino acid variations are observed, 4 of them in α1, 6 in α2 and 3 in the α3 domain (Donadi et al., 2011). The amino acid substitutions may account for the biological function of HLA-G, including peptide binding, isoform production, and ability to polymerize and modulate immune system cells. 406 HLA-G (major histocompatibility complex, class I, G) Yie SM The HLA-G promoter exhibits 29 SNPs to date. Since many of these polymorphisms either coincide with or are closed to the known regulatory elements, they may affect the binding of the corresponding regulatory factors (Tan et al., 2005; Hviid et al., 2006; Hviid et al., 2004a; Hviid et al., 2004b). Polymorphisms located at CpG sites may affect promoter methylation (Ober et al., 2006). In some cases, polymorphism in the promoter region may be in linkage disequilibrium with 3'-UTR variants (Nicolae et al., 2005), and some of them could influence alternative splicing (Auboeuf et al., 2002) and mRNA stability (Rousseau et al., 2003). In contrast to the coding region, the 3'-UTR of the HLA-G locus presents a high degree of variation. Since the 3'-UTR of HLA-G gene exhibits several regulatory elements including AU-rich motifs, a poly-A signal, as well as signals that regulate the spatial and temporal expression of an mRNA, the polymorphic sites may influence mRNA stability, turnover, mobility and splicing pattern. The polymorphic sites at the 3'-UTR seem to bear ranged in several haplotypes (Alvarez et al., 2009; Castelli et al., 2010; Donadi et al., 2011), their influence seems to occur simultaneously. Figure 3. The role of HLA-G in tumor immunoediting. HLA-G is involved in every phase of tumor immunoediting to inhibit host immune response. During the tumor immunoediting process, HLA-G can be activated and up-regulated by many factors. Aberrant expression of HLA-G can: 1) disable effectors of innate and adaptive immunity in the elimination phase; 2) alter antigen presentation and contribute less immunogenic phenotype in the equilibrium phase; and 3) induce immunosuppressive cytokines and peripheral tolerance to the tumor (plus processes described in the two previous phases) in the escape phase. Atlas Genet Cytogenet Oncol Haematol. 2012; 16(6) 407 HLA-G (major histocompatibility complex, class I, G) Yie SM (Yu and Fu, 2006). Also, it has been documented that HLA-G can increase regulatory T cells within TILs in breast and hepatocellular cancers (Chen et al., 2010; Cai et al., 2009). The regulatory T cells are a subset of immune T cells that inhibit the anti-tumor functions of tumor-specific T cells (Shevach, 2002). Therefore, current data suggest that the estimation of HLA-G expression is a novel prognostic marker useful in assessing host immune response since cancer can be explained, at least in part, as an abnormal immune system tolerance to uncontrolled cells (de la CruzMerino et al., 2008). Furthermore, serum soluble HLA-G is increased in various types of cancer patients (Pistoia et al., 2007; Yie and Hu, 2011) including patients with melanoma (Ugurel et al., 2001), acute leukemia (Gros et al., 2006), multiple myeloma (Leleu et al., 2005), neuroblastoma (Morandi et al., 2007), lymphoproliferative disorders (Sebti et al., 2007), breast or ovarian cancer (Singer et al., 2003; Chen et al., 2010; He et al., 2010), non-small cell lung cancer (Cao et al., 2011), esophageal cancer (Cao et al., 2011), colorectal cancer (Zhu et al., 2011; Cao et al., 2011), gastric cancer (Cao et al., 2011) and hepatocellular carcinoma (Wang et al., 2011), when compared to normal healthy controls or benign disease cases. Although numerous and different cancer studies show preferential up-regulation of HLA-G in advanced diseases rather than in initial tumor lesions, currently available HLA-G data do support the notion that HLAG can be used as a potential biomarker in the diagnosis of human carcinomas (Yie and Hu, 2011). Implicated in Various cancers Disease Cancer is essentially considered a complex cell disease caused by abnormalities in the genetic material of transformed cells. However, cancer development is a complicated progressive process that involves a sequence of gene-environment interactions with dysfunctions in multiple systems, including immune functions. The immune system can specifically identify and eliminate tumor cells based on their expression of tumor-specific antigens or molecules induced during malignant cell transformation. This process is referred to as tumor immune surveillance (Swann and Smyth, 2007). Despite tumor immune surveillance, tumors can still develop in the presence of a functioning immune system. This occurs through tumor immunoediting, a process that comprises three major phases (Urosevic and Dummer, 2008): 1) the elimination phase in which most immuno-genic tumor cells are eliminated by cytotoxic T and NK cells; 2) the equilibrium phase in which tumor cells with reduced immunogenicity are selected; and 3) the escape phase in which variants that no longer respond to the host immune system are maintained (Urosevic and Dummer, 2008). HLA-G is involved in every phase of tumor immunoediting by decreasing the elimination of tumor cells, by inhibiting the cytotoxic function of T and NK cells, and by trogocytosis, (i.e. the intercell transference of viable HLA-G molecules), which renders competent cytotoxic cells unresponsive to tumor antigens (LeMaoult et al., 2007; Caumartin et al., 2007) (figure 3). Prognosis HLA-G is aberrantly expressed in many human solid malignant tumors in situ and malignant hematopoietic diseases including breast, ovarian, clear renal cell, colorectal, gastric, esophageal, lung, and hepatocellular cancers, as well as acute myeloid leukaemia and chronic lymphocytic leukemia (B-CLL) (Carosella et al., 2008; Yie and Hu, 2011). The aberrant expression of HLA-G in malignant neoplasm is significantly correlated with poor clinical outcome of patients with colorectal cancer (CRC) (Ye et al., 2007), gastric cancer (GC) (Yie et al., 2007b), non-small cell lung cancer (NSCLC) (Yie et al., 2007c), esophageal squamous cell cancer (ESCC) (Yie et al., 2007a), breast cancer (He et al., 2010), hepatocellular cancers (Cai et al., 2009), and B-CLL (Nückel et al., 2005). This is due to the fact that HLA-G expression favors tumor development and metastasis in every phase of cancer immunoediting by impairing anti-tumor immune responses (Urosevic and Dummer, 2008). A reverse correlation between HLA-G expression in tumors and the degree of tumor-infiltrating lymphocytes (TILs) has been demonstrated in a variety of cancer types (Yie and Hu, 2011). The presence of TILs indicates an anti-tumor cellular immune response Atlas Genet Cytogenet Oncol Haematol. 2012; 16(6) References Kovats S, Main EK, Librach C, Stubblebine M, Fisher SJ, DeMars R. A class I antigen, HLA-G, expressed in human trophoblasts. Science. 1990 Apr 13;248(4952):220-3 Ishitani A, Geraghty DE. Alternative splicing of HLA-G transcripts yields proteins with primary structures resembling both class I and class II antigens. Proc Natl Acad Sci U S A. 1992 May 1;89(9):3947-51 Schmidt CM, Ehlenfeldt RG, Athanasiou MC, Duvick LA, Heinrichs H, David CS, Orr HT. Extraembryonic expression of the human MHC class I gene HLA-G in transgenic mice. Evidence for a positive regulatory region located 1 kilobase 5' to the start site of transcription. J Immunol. 1993 Sep 1;151(5):2633-45 Yelavarthi KK, Schmidt CM, Ehlenfeldt RG, Orr HT, Hunt JS. Cellular distribution of HLA-G mRNA in transgenic mouse placentas. J Immunol. 1993 Oct 1;151(7):3638-45 Fujii T, Ishitani A, Geraghty DE. A soluble form of the HLA-G antigen is encoded by a messenger ribonucleic acid containing intron 4. J Immunol. 1994 Dec 15;153(12):5516-24 Crisa L, McMaster MT, Ishii JK, Fisher SJ, Salomon DR. Identification of a thymic epithelial cell subset sharing expression of the class Ib HLA-G molecule with fetal trophoblasts. J Exp Med. 1997 Jul 21;186(2):289-98 Gao GF, Willcox BE, Wyer JR, Boulter JM, O'Callaghan CA, Maenaka K, Stuart DI, Jones EY, Van Der Merwe PA, Bell JI, Jakobsen BK. Classical and nonclassical class I major 408 HLA-G (major histocompatibility complex, class I, G) Yie SM histocompatibility complex molecules exhibit subtle conformational differences that affect binding to CD8alphaalpha. J Biol Chem. 2000 May 19;275(20):15232-8 apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation. Eur J Immunol. 2003 Jan;33(1):125-34 Ibrahim EC, Morange M, Dausset J, Carosella ED, Paul P. Heat shock and arsenite induce expression of the nonclassical class I histocompatibility HLA-G gene in tumor cell lines. Cell Stress Chaperones. 2000 Jul;5(3):207-18 Gonen-Gross T, Achdout H, Gazit R, Hanna J, Mizrahi S, Markel G, Goldman-Wohl D, Yagel S, Horejsí V, Levy O, Baniyash M, Mandelboim O. Complexes of HLA-G protein on the cell surface are important for leukocyte Ig-like receptor-1 function. J Immunol. 2003 Aug 1;171(3):1343-51 Paul P, Cabestre FA, Ibrahim EC, Lefebvre S, Khalil-Daher I, Vazeux G, Quiles RM, Bermond F, Dausset J, Carosella ED. Identification of HLA-G7 as a new splice variant of the HLA-G mRNA and expression of soluble HLA-G5, -G6, and -G7 transcripts in human transfected cells. Hum Immunol. 2000 Nov;61(11):1138-49 Ishitani A, Sageshima N, Lee N, Dorofeeva N, Hatake K, Marquardt H, Geraghty DE. Protein expression and peptide binding suggest unique and interacting functional roles for HLA-E, F, and G in maternal-placental immune recognition. J Immunol. 2003 Aug 1;171(3):1376-84 Dietrich J, Cella M, Colonna M. Ig-like transcript 2 (ILT2)/leukocyte Ig-like receptor 1 (LIR1) inhibits TCR signaling and actin cytoskeleton reorganization. J Immunol. 2001 Feb 15;166(4):2514-21 Kuersten S, Goodwin EB. The power of the 3' UTR: translational control and development. Nat Rev Genet. 2003 Aug;4(8):626-37 LeMaoult J, Le Discorde M, Rouas-Freiss N, Moreau P, Menier C, McCluskey J, Carosella ED. Biology and functions of human leukocyte antigen-G in health and sickness. Tissue Antigens. 2003 Oct;62(4):273-84 Lefebvre S, Berrih-Aknin S, Adrian F, Moreau P, Poea S, Gourand L, Dausset J, Carosella ED, Paul P. A specific interferon (IFN)-stimulated response element of the distal HLAG promoter binds IFN-regulatory factor 1 and mediates enhancement of this nonclassical class I gene by IFN-beta. J Biol Chem. 2001 Mar 2;276(9):6133-9 Park B, Ahn K. An essential function of tapasin in quality control of HLA-G molecules. J Biol Chem. 2003 Apr 18;278(16):14337-45 Lila N, Rouas-Freiss N, Dausset J, Carpentier A, Carosella ED. Soluble HLA-G protein secreted by allo-specific CD4+ T cells suppresses the allo-proliferative response: a CD4+ T cell regulatory mechanism. Proc Natl Acad Sci U S A. 2001 Oct 9;98(21):12150-5 Rebmann V, Regel J, Stolke D, Grosse-Wilde H. Secretion of sHLA-G molecules in malignancies. Semin Cancer Biol. 2003 Oct;13(5):371-7 Rousseau P, Le Discorde M, Mouillot G, Marcou C, Carosella ED, Moreau P. The 14 bp deletion-insertion polymorphism in the 3' UT region of the HLA-G gene influences HLA-G mRNA stability. Hum Immunol. 2003 Nov;64(11):1005-10 Park B, Lee S, Kim E, Chang S, Jin M, Ahn K. The truncated cytoplasmic tail of HLA-G serves a quality-control function in post-ER compartments. Immunity. 2001 Aug;15(2):213-24 Shiroishi M, Tsumoto K, Amano K, Shirakihara Y, Colonna M, Braud VM, Allan DS, Makadzange A, Rowland-Jones S, Willcox B, Jones EY, van der Merwe PA, Kumagai I, Maenaka K. Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G. Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8856-61 Rebmann V, van der Ven K, Pässler M, Pfeiffer K, Krebs D, Grosse-Wilde H. Association of soluble HLA-G plasma levels with HLA-G alleles. Tissue Antigens. 2001 Jan;57(1):15-21 Ugurel S, Rebmann V, Ferrone S, Tilgen W, Grosse-Wilde H, Reinhold U. Soluble human leukocyte antigen--G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy. Cancer. 2001 Jul 15;92(2):369-76 Singer G, Rebmann V, Chen YC, Liu HT, Ali SZ, Reinsberg J, McMaster MT, Pfeiffer K, Chan DW, Wardelmann E, GrosseWilde H, Cheng CC, Kurman RJ, Shih IeM. HLA-G is a potential tumor marker in malignant ascites. Clin Cancer Res. 2003 Oct 1;9(12):4460-4 Auboeuf D, Hönig A, Berget SM, O'Malley BW. Coordinate regulation of transcription and splicing by steroid receptor coregulators. Science. 2002 Oct 11;298(5592):416-9 Boyson JE, Erskine R, Whitman MC, Chiu M, Lau JM, Koopman LA, Valter MM, Angelisova P, Horejsi V, Strominger JL. Disulfide bond-mediated dimerization of HLA-G on the cell surface. Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):161805 Brown D, Trowsdale J, Allen R. The LILR family: modulators of innate and adaptive immune pathways in health and disease. Tissue Antigens. 2004 Sep;64(3):215-25 Hviid TV, Larsen LG, Hoegh AM, Bzorek M. HLA-G expression in placenta in relation to HLA-G genotype and polymorphisms. Am J Reprod Immunol. 2004a Sep;52(3):212-7 Hsu KC, Chida S, Geraghty DE, Dupont B. The killer cell immunoglobulin-like receptor (KIR) genomic region: geneorder, haplotypes and allelic polymorphism. Immunol Rev. 2002 Dec;190:40-52 Hviid TV, Rizzo R, Christiansen OB, Melchiorri L, Lindhard A, Baricordi OR. HLA-G and IL-10 in serum in relation to HLA-G genotype and polymorphisms. Immunogenetics. 2004b Jun;56(3):135-41 Puppo F, Contini P, Ghio M, Indiveri F. Soluble HLA class I molecules/CD8 ligation trigger apoptosis of CD8+ cells by Fas/Fas-ligand interaction. ScientificWorldJournal. 2002 Feb 12;2:421-3 Leleu X, Le Friec G, Facon T, Amiot L, Fauchet R, Hennache B, Coiteux V, Yakoub-Agha I, Dubucquoi S, Avet-Loiseau H, Mathiot C, Bataille R, Mary JY. Total soluble HLA class I and soluble HLA-G in multiple myeloma and monoclonal gammopathy of undetermined significance. Clin Cancer Res. 2005 Oct 15;11(20):7297-303 Shevach EM. CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol. 2002 Jun;2(6):389400 Carosella ED, Moreau P, Le Maoult J, Le Discorde M, Dausset J, Rouas-Freiss N. HLA-G molecules: from maternal-fetal tolerance to tissue acceptance. Adv Immunol. 2003;81:199252 Nicolae D, Cox NJ, Lester LA, Schneider D, Tan Z, Billstrand C, Kuldanek S, Donfack J, Kogut P, Patel NM, Goodenbour J, Howard T, Wolf R, Koppelman GH, White SR, Parry R, Postma DS, Meyers D, Bleecker ER, Hunt JS, Solway J, Ober C. Fine mapping and positional candidate studies identify HLA-G as an Contini P, Ghio M, Poggi A, Filaci G, Indiveri F, Ferrone S, Puppo F. Soluble HLA-A,-B,-C and -G molecules induce Atlas Genet Cytogenet Oncol Haematol. 2012; 16(6) 409 HLA-G (major histocompatibility complex, class I, G) Yie SM asthma susceptibility gene on chromosome 6p21. Am J Hum Genet. 2005 Feb;76(2):349-57 indicator for patients with colorectal cancer. Mod Pathol. 2007 Mar;20(3):375-83 Nückel H, Rebmann V, Dürig J, Dührsen U, Grosse-Wilde H. HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia. Blood. 2005 Feb 15;105(4):1694-8 Yie SM, Yang H, Ye SR, Li K, Dong DD, Lin XM. Expression of HLA-G is associated with prognosis in esophageal squamous cell carcinoma. Am J Clin Pathol. 2007a Dec;128(6):1002-9 Yie SM, Yang H, Ye SR, Li K, Dong DD, Lin XM. Expression of human leukocyte antigen G (HLA-G) correlates with poor prognosis in gastric carcinoma. Ann Surg Oncol. 2007b Oct;14(10):2721-9 Rizzo R, Mapp CE, Melchiorri L, Maestrelli P, Visentin A, Ferretti S, Bononi I, Miotto D, Baricordi OR. Defective production of soluble HLA-G molecules by peripheral blood monocytes in patients with asthma. J Allergy Clin Immunol. 2005 Mar;115(3):508-13 Yie SM, Yang H, Ye SR, Li K, Dong DD, Lin XM. Expression of human leucocyte antigen G (HLA-G) is associated with prognosis in non-small cell lung cancer. Lung Cancer. 2007c Nov;58(2):267-74 Tan Z, Shon AM, Ober C. Evidence of balancing selection at the HLA-G promoter region. Hum Mol Genet. 2005 Dec 1;14(23):3619-28 Apps R, Gardner L, Moffett A. A critical look at HLA-G. Trends Immunol. 2008 Jul;29(7):313-21 Yan WH, Fan LA. Residues Met76 and Gln79 in HLA-G alpha1 domain involve in KIR2DL4 recognition. Cell Res. 2005 Mar;15(3):176-82 Carosella ED, Moreau P, Lemaoult J, Rouas-Freiss N. HLA-G: from biology to clinical benefits. Trends Immunol. 2008 Mar;29(3):125-32 Gros F, Sebti Y, de Guibert S, Branger B, Bernard M, Fauchet R, Amiot L. Soluble HLA-G molecules increase during acute leukemia, especially in subtypes affecting monocytic and lymphoid lineages. Neoplasia. 2006 Mar;8(3):223-30 de la Cruz-Merino L, Grande-Pulido E, Albero-Tamarit A, Codes-Manuel de Villena ME. Cancer and immune response: old and new evidence for future challenges. Oncologist. 2008 Dec;13(12):1246-54 Hviid TV, Rizzo R, Melchiorri L, Stignani M, Baricordi OR. Polymorphism in the 5' upstream regulatory and 3' untranslated regions of the HLA-G gene in relation to soluble HLA-G and IL-10 expression. Hum Immunol. 2006 JanFeb;67(1-2):53-62 Morandi F, Raffaghello L, Bianchi G, Meloni F, Salis A, Millo E, Ferrone S, Barnaba V, Pistoia V. Immunogenicity of human mesenchymal stem cells in HLA-class I-restricted T-cell responses against viral or tumor-associated antigens. Stem Cells. 2008 May;26(5):1275-87 Ober C, Billstrand C, Kuldanek S, Tan Z. The miscarriageassociated HLA-G -725G allele influences transcription rates in JEG-3 cells. Hum Reprod. 2006 Jul;21(7):1743-8 Urosevic M, Dummer R. Human leukocyte antigen-G and cancer immunoediting. Cancer Res. 2008 Feb 1;68(3):627-30 Shiroishi M, Kuroki K, Ose T, Rasubala L, Shiratori I, Arase H, Tsumoto K, Kumagai I, Kohda D, Maenaka K. Efficient leukocyte Ig-like receptor signaling and crystal structure of disulfide-linked HLA-G dimer. J Biol Chem. 2006 Apr 14;281(15):10439-47 Alvarez M, Piedade J, Balseiro S, Ribas G, Regateiro F. HLAG 3'-UTR SNP and 14-bp deletion polymorphisms in Portuguese and Guinea-Bissau populations. Int J Immunogenet. 2009 Dec;36(6):361-6 Cai MY, Xu YF, Qiu SJ, Ju MJ, Gao Q, Li YW, Zhang BH, Zhou J, Fan J. Human leukocyte antigen-G protein expression is an unfavorable prognostic predictor of hepatocellular carcinoma following curative resection. Clin Cancer Res. 2009 Jul 15;15(14):4686-93 Yie SM, Xiao R, Librach CL. Progesterone regulates HLA-G gene expression through a novel progesterone response element. Hum Reprod. 2006 Oct;21(10):2538-44 Yu P, Fu YX. Tumor-infiltrating T lymphocytes: friends or foes? Lab Invest. 2006 Mar;86(3):231-45 Flajollet S, Poras I, Carosella ED, Moreau P. RREB-1 is a transcriptional repressor of HLA-G. J Immunol. 2009 Dec 1;183(11):6948-59 Caumartin J, Favier B, Daouya M, Guillard C, Moreau P, Carosella ED, LeMaoult J. Trogocytosis-based generation of suppressive NK cells. EMBO J. 2007 Mar 7;26(5):1423-33 Moreau P, Flajollet S, Carosella ED. Non-classical transcriptional regulation of HLA-G: an update. J Cell Mol Med. 2009 Sep;13(9B):2973-89 LeMaoult J, Caumartin J, Daouya M, Favier B, Le Rond S, Gonzalez A, Carosella ED. Immune regulation by pretenders: cell-to-cell transfers of HLA-G make effector T cells act as regulatory cells. Blood. 2007 Mar 1;109(5):2040-8 Castelli EC, Mendes-Junior CT, Deghaide NH, de Albuquerque RS, Muniz YC, Simões RT, Carosella ED, Moreau P, Donadi EA. The genetic structure of 3'untranslated region of the HLAG gene: polymorphisms and haplotypes. Genes Immun. 2010 Mar;11(2):134-41 Morandi F, Levreri I, Bocca P, Galleni B, Raffaghello L, Ferrone S, Prigione I, Pistoia V. Human neuroblastoma cells trigger an immunosuppressive program in monocytes by stimulating soluble HLA-G release. Cancer Res. 2007 Jul 1;67(13):6433-41 Chen HX, Lin A, Shen CJ, Zhen R, Chen BG, Zhang X, Cao FL, Zhang JG, Yan WH. Upregulation of human leukocyte antigen-G expression and its clinical significance in ductal breast cancer. Hum Immunol. 2010 Sep;71(9):892-8 Pistoia V, Morandi F, Wang X, Ferrone S. Soluble HLA-G: Are they clinically relevant? Semin Cancer Biol. 2007 Dec;17(6):469-79 He X, Dong DD, Yie SM, Yang H, Cao M, Ye SR, Li K, Liu J, Chen J. HLA-G expression in human breast cancer: implications for diagnosis and prognosis, and effect on allocytotoxic lymphocyte response after hormone treatment in vitro. Ann Surg Oncol. 2010 May;17(5):1459-69 Sebti Y, Le Maux A, Gros F, De Guibert S, Pangault C, RouasFreiss N, Bernard M, Amiot L. Expression of functional soluble human leucocyte antigen-G molecules in lymphoproliferative disorders. Br J Haematol. 2007 Jul;138(2):202-12 Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest. 2007 May;117(5):1137-46 Cao M, Yie SM, Liu J, Ye SR, Xia D, Gao E. Plasma soluble HLA-G is a potential biomarker for diagnosis of colorectal, gastric, esophageal and lung cancer. Tissue Antigens. 2011 Aug;78(2):120-8 Ye SR, Yang H, Li K, Dong DD, Lin XM, Yie SM. Human leukocyte antigen G expression: as a significant prognostic Atlas Genet Cytogenet Oncol Haematol. 2012; 16(6) 410 HLA-G (major histocompatibility complex, class I, G) Yie SM Donadi EA, Castelli EC, Arnaiz-Villena A, Roger M, Rey D, Moreau P. Implications of the polymorphism of HLA-G on its function, regulation, evolution and disease association. Cell Mol Life Sci. 2011 Feb;68(3):369-95 human malignancies. Histol Histopathol. 2011 Mar;26(3):409-20 Zhu CB, Wang CX, Zhang X, Zhang J, Li W. Serum sHLA-G levels: a useful indicator in distinguishing colorectal cancer from benign colorectal diseases. Int J Cancer. 2011 Feb 1;128(3):617-22 Wang Y, Ye Z, Meng XQ, Zheng SS. Expression of HLA-G in patients with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2011 Apr;10(2):158-63 This article should be referenced as such: Yie SM, Hu Z. Human leukocyte antigen-G (HLA-G) as a marker for diagnosis, prognosis and tumor immune escape in Atlas Genet Cytogenet Oncol Haematol. 2012; 16(6) Yie SM. HLA-G (major histocompatibility complex, class I, G). Atlas Genet Cytogenet Oncol Haematol. 2012; 16(6):403-411. 411